Category

News
A New Zealand research team on the cusp of a cancer breakthrough has been gifted a significant financial boost thanks to the world’s oldest fraternal organisation. Over the next two years, Freemasons New Zealand will donate $600,000 to support the Wellington-based Malaghan Institute’s world-leading CAR-T cell therapy research. For Freemasons’ grand master Mark Winger  the partnership was a no-brainer,...
Continue Reading
Each of the many BCMA-targeted chimeric antigen receptor (CAR) T cells in development demonstrate a different efficacy and safety profile, and each have different constructs. None of the agents have reached the FDA yet, but data for many of the agents were presented at the 2018 ASH Annual Meeting. Showing promising data in the phase...
Continue Reading
The 11 patients had already received treatment after treatment for their cancers, some as many as 20 different courses of therapy. Yet their myelomas, almost all classified by doctors as “high risk,” kept coming back. Their options faded away. Then they joined a clinical trial to be the first people ever to receive a new experimental, immune-harnessing...
Continue Reading
An international phase-2 trial of a CAR-T cell therapy—to be published on-line Dec. 1 in the New England Journal of Medicine (and presented at the ASH annual meeting in San Diego)—found that 52 percent of patients responded favorably to the therapy; 40 percent had a complete response and 12 percent had a partial response. One year later,...
Continue Reading
Ken Romeril, CEO Myeloma New Zealand Charitable Trust invites you to the Myeloma New Zealand Christmas Function 12 December, 5.00pm at BNZ Partners Centre, Level 10 Ricoh House, 1 Victoria St Wellington RSVP by Friday 7 December to contact@multiplemyeloma.org.nz
Continue Reading
The U.S. Food and Drug Administration (FDA) has granted P-BCMA-101, Poseida Therapeutics’ CAR T-cell therapy and lead product candidate, the Regenerative Medicine Advanced Therapy (RMAT) designation for the treatment of relapsed or refractory multiple myeloma. Preliminary results from a Phase 1 trial (NCT03288493) suggest the candidate is safe and may have superior effectiveness compared with other CAR T-cell therapies. The RMAT designation...
Continue Reading
There has been activity with chimeric antigen receptor (CAR) T cells in patients with relapsed diffuse large B-cell lymphoma (DLBCL), but Charalambos (Babis) Andreadis, MD, MSCE, says there are still several things to consider before choosing this treatment option for a patient. “It’s something that we’re very excited about, especially for patients with relapsed disease. We also...
Continue Reading
From better-understanding how to improve response rates in multiple myeloma patients to identifying why some patients with other types of cancer are resistant in the first place, research from the Abramson Cancer Center of the University of Pennsylvania continues to pace the field in expanding knowledge of cellular therapies for cancer care. Penn researchers will...
Continue Reading
The Center for International Blood and Marrow Transplant Research, through an alliance with Novartis, aims to track the long-term outcomes of patients treated with chimeric antigen receptor T-cell therapies. The center will collect data from children and adults treated with tisagenlecleucel (Kymriah, Novartis) who agree to participate in the center’s cellular therapy registry. “We are...
Continue Reading
Transplant remains the standard of care for eligible patients with newly diagnosed multiple myeloma, although the optimal induction regimen and value of consolidation is still debated, explained Ravi Vij, MD. However, in patients who are ineligible for transplant, Vij noted that proteasome inhibitors and monoclonal antibodies are showing promise in the frontline setting and may...
Continue Reading
1 2 3 4 5 14

Floor 7, 90 The Terrace
Wellington Central
New Zealand